This study seeks to elucidate whether EA at ST36 can attenuate HFD‐induced AD pathologies, with a particular focus on the underlying molecular mechanisms involving TFEB/TFE3‐mediated ALP modulation and its relevance to AD and metabolic dysfunction. Here, TFEB is linked to Alzheimer disease.